HD CAG repeat implicates a dominant property of huntingtin in mitochondrial energy metabolism

Human Molecular Genetics

Volumn 14, Issue 19, 2005, Pages 2871-2880

  Seong, Ihn Sik ^a   Ivanova, Elena ^a   Lee, Jong Min ^a   Choo, Yeun Su ^b   Fossale, Elisa ^a   Anderson, Mary Anne ^a   Gusella, James F ^a   Laramie, Jason M ^c   Myers, Richard H ^b   Lesort, Mathieu ^b   MacDonald, Marcy E ^a  

^a Center for Human Genetic Research   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE NUCLEOTIDE TRANSLOCASE; ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; CALCIUM; HUNTINGTIN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; POLYGLUTAMINE;

ALLELE; ARTICLE; CALCIUM CELL LEVEL; CALCIUM TRANSPORT; CELL ENERGY; CELL SPECIFICITY; CONTROLLED STUDY; CORPUS STRIATUM; DNA POLYMORPHISM; ENERGY METABOLISM; ENZYME ACTIVITY; FLOW CYTOMETRY; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC CODE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUNTINGTON CHOREA; IMMUNOBLOTTING; LYMPHOBLASTOID CELL LINE; METABOLIC INHIBITION; MITOCHONDRIAL ENERGY TRANSFER; NERVE CELL NECROSIS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; AGE OF ONSET; ALLELES; CALCIUM SIGNALING; CELLS, CULTURED; DNA REPEAT EXPANSION; ENERGY METABOLISM; HUMANS; HUNTINGTON DISEASE; MITOCHONDRIA; NERVE TISSUE PROTEINS; NUCLEAR PROTEINS; PEPTIDES; PHOSPHORYLATION; POLYMORPHISM, GENETIC; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 26444441008     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddi319     Document Type: Article

References (58)

1. Martin, J.B. and Gusella, J.F. (1986) Huntington's disease. Pathogenesis and management. N. Engl. J. Med., 315, 1267-1276.
2. The Huntington's Disease Collaborative Research Group. (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell, 72, 971-983.
3. Takano, H. and Gusella, J.F. (2002) The predominantly HEAT-like motif structure of huntingtin and its association and coincident nuclear entry with dorsal, an NF-kB/Rel/dorsal family transcription factor. BMC Neurosci., 3, 15.
4. Gusella, J.F. and MacDonald, M.E. (2000) Molecular genetics: Unmasking polyglutamine triggers in neurodegeneratioe disease. Nat. Rev. Neurosci., 1, 109-115.
5. Sharp, A.H., Loev, S.J., Schilling, G., Li, S.H., Li, X.J., Bao, J., Wagster, M.V., Kotzuk, J.A., Steiner, J.P., Lo, A. et al. (1995) Widespread expression of Huntington's disease gene (IT15) protein product. Neuron, 14, 1065-1074.
6. La Spada, A.R. and Taylor, J.P. (2003) Polyglutamines placed into context. Neuron, 38, 681-684.
7. Brouillet, E. and Hantraye, P. (1995) Effects of chronic MPTP and 3-nitropropionic acid in nonhuman primates. Curr. Opin. Neurol., 8, 469-473.
8. Beal, M.F., Brouillet, E., Jenkins, B.G., Ferrante, R.J., Kowall, N.W., Miller, J.M., Storey, E., Srivastava, R., Rosen, B.R. and Hyman, B.T. (1993) Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J. Neurosci., 13, 4181-4192.
9. Albin, R.L. and Greenamyre, J.T. (1992) Alternative excitotoxic hypotheses. Neurology, 42, 733-738.
10. Beal, M.F., Brouillet, E., Jenkins, B., Henshaw, R., Rosen, B. and Hyman, B.T. (1993) Age-dependent striatal excitotoxic lesions produced by the endogenous mitochondrial inhibitor malonate. J. Neurochem., 61, 1147-1150.
11. Greene, J.G. and Greenamyre, J.T. (1996) Bioenergetics and glutamate excitotoxicity. Prog. Neurobiol., 48, 613-634.
12. Gu, M., Gash, M.T., Mann, V.M., Javoy-Agid, F., Cooper, J.M. and Schapira, A.H. (1996) Mitochondrial defect in Huntington's disease caudate nucleus. Ann. Neurol., 39, 385-389.
13. Koroshetz, W.J., Jenkins, B.G., Rosen, B.R. and Beal, M.F. (1997) Energy metabolism defects in Huntington's disease and effects of coenzyme Q10. Ann. Neurol., 41, 160-165.
14. Arenas. J., Campos, Y., Ribacoba, R., Martin, M.A., Rubio, J.C., Ablanedo, P. and Cabello, A. (1998) Complex I defect in muscle from patients with Huntington's disease. Ann. Neurol., 43, 397-400.
15. Tabrizi, S.J. and Schapira, A.H. (1999) Secondary, abnormalities of mitochondrial DNA associated with neurodegeneration. Biochem. Soc. Symp., 66, 99-110.
16. Lodi, R., Schapira, A.H., Manners, D., Styles, P., Wood, N.W., Taylor, D.J. and Warner, T.T. (2000) Abnormal in vivo skeletal muscle energy metabolism in Huntington's disease and dentatorubropallidoluysian atrophy. Ann. Neurol., 48, 72-76.
17. Schapira, A. and Lodi, R. (2004) Assessment of in vitro and in vivo mitochondrial function in Friedreich's ataxia and Huntington's disease. Methods Mol. Biol., 277, 293-307.
18. Saft, C., Zange, J., Andrich, J., Muller, K., Lindenberg, K., Landwehrmeyer, B., Vorgerd, M., Kraus, P.H., Przuntek, H. and Schols, L. (2005) Mitochondrial impairment in patients and asymptomatic mutation carriers of Huntington's disease. Mov. Disord., 20, 674-679.
19. Sawa, A., Wiegand, G.W., Cooper, J., Margolis, R.L., Sharp, A.H., Lawler, J.F., Jr, Greenamyre, J.T., Snyder, S.H. and Ross, C.A. (1999) Increased apoptosis of Huntington disease lymphoblasts associated with repeat length-dependent mitochondrial depolarization. Nat. Med., 5, 1194-1198.
20. MacDonald, M.E., Gines, S., Gusella, J.F. and Wheeler, V.C. (2003) Huntington's disease. Neuromolecular Med., 4, 7-20.
21. Levine, M.S., Klapstein, G.J., Koppel, A., Gruen, E., Cepeda, C., Vargas, M.E., Jokel, E.S., Carpenter, E.M., Zanjani, H., Hurst, R.S. et al. (1999) Enhanced sensitivity to N-methyl-D-aspartate receptor activation in transgenic and knockin mouse models of Huntington's disease. J. Neurosci. Res., 58, 515-532.
22. Gines, S., Ivanova, E., Seong, I.S., Saura, C.A. and MacDonald, M.E. (2003) Enhanced Akt signaling is an early pro-survival response that reflects N-methyl-D-aspartate receptor activation in Huntington's disease knock-in striatal cells. J. Biol. Chem., 278, 50514-50522.
23. Gines, S., Seong, I.S., Fossale, E., Ivanova, E., Trettel, F., Gusella, J.F., Wheeler, V.C., Persichetti, F. and MacDonald, M.E. (2003) Specific progressive cAMP reduction implicates energy deficit in presymptomatic Huntington's disease knock-in mice. Hum. Mol. Genet., 12, 497-508.
24. Zeron, M.M., Fernandes, H.B., Krebs, C., Shehadeh, J., Wellington, C.L., Leavitt, B.R., Baimbridge, K.G., Hayden, M.R. and Raymond, L.A. (2004) Potentiation of NMDA receptor-mediated excitotoxicity linked with intrinsic apoptotic pathway in YAC transgenic mouse model of Huntington's disease. Mol. Cell. Neurosci., 25, 469-479.
25. 2+ signaling and apoptosis of medium spiny neurons in Huntington's disease. Proc. Natl Acad Sci. USA, 102, 2602-2607.
26. Panov, A.V., Gutekunst, C.A., Leavitt, B.R., Hayden, M.R., Burke, J.R., Strittmatter, W.J. and Greenamyre, J.T. (2002) Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Nat. Neurosci., 5, 731-736.
27. Trettel, F., Rigamonti, D., Hilditch-Maguire, P., Wheeler, V.C., Sharp, A.H., Persichetti, F., Cattaneo, E. and MacDonald. M.E. (2000) Dominant phenotypes produced by the HD mutation in STHdh(Q111) striatal cells. Hum. Mol. Genet., 9, 2799-2809.
28. Ruan, Q., Lesort, M., MacDonald. M.E. and Johnson, G.V. (2004) Striatal cells from mutant huntingtin knock-in mice are selectively vulnerable to mitochondrial complex II inhibitor-induced cell death through a non-apoptotic pathway. Hum. Mol. Genet., 13, 669-681.
29. Halestrap, A.P. and Brennerb, C. (2003) The adenine nucleotide translocase: A central component of the mitochondrial permeability transition pore and key player in cell death. Curr. Med. Chem., 10, 1507-1525.
30. Grunewald, T. and Beal, M.F. (1999) Bioenergetics in Huntington's disease. Ann. NY Acad. Sci., 893, 203-213.
31. Carter, A.G. and Sabatini, B.L. (2004) State-dependent calcium signaling in dendritic spines of striatal medium spiny neurons. Neuron, 44, 483-493.
32. Milakovic, T. and Johnson, G.V. (2005) Mitochondrial respiration and ATP production are significantly impaired in striatal cells expressing mutant huntingtin. J. Biol. Chem. (Epub ahead of print).
33. 2+-induced permeability transition in human lymphoblastoid cell mitochondria from normal and Huntington's disease individuals. Mol. Cell. Biochem., 269, 143-152.
34. 2+-dependent depolarization of rat and human mitochondria: Relevance to Huntington's disease. Arch. Biochem. Biophys., 410, 1-6.
35. Sawa, A. (2001) Mechanisms for neuronal cell death and dysfunction in Huntington's disease: Pathological cross-talk between the nucleus and the mitochondria? J. Mol. Med., 79, 375-381.
36. Schuh, R.A., Kristian, T. and Fiskum, G. (2005) Calcium-dependent dephosphorylation of brain mitochondrial calcium/cAMP response element binding protein (CREB). J. Neurochem., 92, 388-394.
37. Kushnareva, Y.E., Wiley, S.E., Ward, M.W., Andreyev, A.Y. and Murphy, A.N. (2005) Excitotoxic injury to mitochondria isolated from cultured neurons. J. Biol. Chem. 280, 28894-28902.
38. Michalik, A. and van Broeckhoven, C. (2003) Pathogenesis of polyglutamine disorders: Aggregation revisited. Hum. Mol. Genet., 12(Spec no. 2), R173-R186.
39. Choo, Y.S., Johnson, G.V., MacDonald, M., Detloff, P.J. and Lesort, M. (2004) Mutant huntingtin directly increases susceptibility of mitochondria to the calcium-induced permeability transition and cytochrome c release. Hum. Mol. Genet., 13, 1407-1420.
40. Sun, Y., Savanenin, A., Reddy, P.H. and Liu, Y.F. (2001) Polyglutamine-expanded huntingtin promotes sensitization of N methyl-D-aspartate receptors via post-synaptic density 95. J. Biol. Chem., 276, 24713-24718.
41. Bezprozvanny, I. and Hayden, M.R. (2004) Deranged neuronal calcium signaling and Huntington disease. Biochem. Biophys. Res. Commun., 322, 1310-1317.
42. Zuccato, C., Tartari, M., Crotti, A., Goffredo. D., Valenza, M., Conti, L., Cataudella, T., Leavitt, B.R., Hayden, M.R., Timmusk, T. et al. (2003) Huntingtin interact with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes. Nat. Genet., 35, 76-83.
43. Yohrling, G.J., Farrell, L.A., Hollenberg, A.N. and Cha, J.H. (2003) Mutant huntingtin increases nuclear corepressor function and enhances ligand-dependent nuclear hormone receptor activation. Mol. Cell. Neurosci., 23, 28-38.
44. Sugars, K.L. and Rubinsztein, D.C. (2003) Transcriptional abnormalities in Huntington disease. Trends Genet., 19, 233-238.
45. Cha, J.H. (2000) Transcriptional dysregulation in Huntington's disease. Trends Neurosci., 23, 387-392.
46. Nagata, E., Sawa, A., Ross, C.A. and Snyder, S.H. (2004) Autophagosome-like vacuole formation in Huntington's disease lymphoblasts. Neuroreport, 15, 1325-1328.
47. Ravikumar, B., Stewart, A., Kita, H., Kato, K., Duden, R. and Rubinsztein, D.C. (2003) Raised intracellular glucose concentrations reduce aggregation and cell death caused by mutant huntingtin exon 1 by decreasing mTOR phosphorylation and inducing autophabry. Hum. Mol. Genet., 12, 985-994.
48. Trushina, E., Heldebrant, M.P., Perez-Terzic, C.M., Bortolon, R., Kovtun, I.V., Badger. J.D., II, Terzic, A., Estevez, A., Windebank, A.J., Dyer, R.B. et al. (2003) Microtubule destabilization and nuclear entry are sequential steps leading to toxicity in Huntington's disease. Proc. Natl Acad. Sci. USA, 100, 12171-12176.
49. Diprospero, N.A., Chen, E.Y., Charles, V., Plomann, M., Kordower, J.H. and Tagle, D.A. (2004) Early changes in Huntington's disease patient brains involve alterations in cytoskeletal and synaptic elements. J. Neurocytol., 33, 517-533.
50. Gauthier. L.R., Charrin, B.C., Borrell-Pages, M., Dompierre, J.P., Rangone, H., Cordelieres, F.P., de Mey, J., MacDonald, M.E., Lessmann, V., Humbert, S. et al. (2004) Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell, 118, 127-138.
51. Humbert, S., Bryson, E.A., Cordelieres, F.P., Connors, N.C., Datta, S.R., Finkbeiner, S., Greenberg, M.E. and Saudou, F. (2002) The IGF-1/ Akt pathway is neuroprotective in Huntington's disease and involves Huntingtin phosphorylation by Akt. Dev. Cell, 2, 831-837.
52. Mattson, M.P., Maudsley, S. and Martin, B. (2004) A neural signaling triumvirate that influences ageing and age-related disease: Insulin/ IGF-1, BDNF and serotonin. Ageing Res. Rev., 3, 445-464.
53. Gottlieb, R.A. and Adachi, S. (2000) Nitrogen cavitation for cell disruption to obtain mitochondria from cultured cells. Methods Enzymol., 322, 213-221.
54. Pallotti, F. and Lenaz, G. (2001) Isolation and subfractionation of mitochondria from animal cells and tissue culture lines. Methods Cell Biol., 65, 1-35.
55. Pfaff, E., Heldt, H.W. and Klingenberg. M. (1969) Adenine nucleotide translocation of mitochondria. Kinetics of the adenine nucleotide exchange. Eur. J. Biochem., 10, 484-493.
56. Belzacq, A.S., Vieira, H.L., Verrier, F., Vandecasteele, G., Cohen, I., Prevost, M.C., Larquet, E., Pariselli, F., Petit, P.X., Kahn, A. et al. (2003) Bcl-2 and Bax modulate adenine nucleotide translocase activity. Cancer Res., 63, 541-546.
57. Barbiero, G., Duranti, F., Bonelli, G., Amenta, J.S. and Baccino, F.M. (1995) Intracellular ionic variations in the apoptotic death of L cells by inhibitors of cell cycle progression. Exp Cell Res., 217, 410-418.
58. Persichetti, F., Carlee, L., Faber, P.W., McNeil, S.M., Ambrose, C.M., Srinidhi, J., Anderson, M., Barnes, G.T., Gusella, J.F. and MacDonald. M.E. (1996) Differential expression of normal and mutant Huntington's disease gene alleles. Neurobiol. Dis., 3, 183-190.